LNK01001

DRUG4 trials

Sponsors

Lynk Pharmaceuticals Co., Ltd

Conditions

Ankylosing SpondylitisAtopic DermatitisRheumatoid Arthritis

Phase 2

A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis

CompletedNCT06085534

Lynk Pharmaceuticals Co., LtdAnkylosing Spondylitis

Start: 2022-01-06End: 2023-06-20Updated: 2023-10-27

Phase 3

A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)

Active, not recruitingNCT06276998

Lynk Pharmaceuticals Co., LtdRheumatoid Arthritis

Start: 2023-12-12End: 2026-11-20Target: 430Updated: 2026-01-14

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

CompletedNCT06277245

Lynk Pharmaceuticals Co., LtdAtopic Dermatitis

Start: 2024-02-06End: 2026-01-12Updated: 2026-04-13

A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

RecruitingNCT07237568

Lynk Pharmaceuticals Co., LtdAnkylosing Spondylitis

Start: 2025-08-29End: 2027-09-30Target: 352Updated: 2025-11-20